MIR497

Summary

MIR497 (microRNA 497, HGNC:32088) is a microRNA gene on chromosome 17p13.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574456 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32088
Approved symbol	MIR497
Name	microRNA 497
Location	17p13.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-497
Ensembl gene	ENSG00000284027
Ensembl biotype	miRNA
OMIM	615672
Entrez	574456
RNAcentral	URS000062BB4A — miRNA, 112 nt, 15 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385056

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385056 — 1 exons

Exon	Start	End
ENSE00001500062	7017911	7018022

Expression profiles

Bgee: expression breadth broad, 12 present calls, max score 66.80.

Top tissues by expression

12 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
muscle layer of sigmoid colon	UBERON:0035805	66.80	gold quality
nucleus accumbens	UBERON:0001882	65.84	gold quality
left coronary artery	UBERON:0001626	65.66	gold quality
heart	UBERON:0000948	65.62	gold quality
transverse colon	UBERON:0001157	64.99	gold quality
skin of abdomen	UBERON:0001416	61.34	gold quality
skin of leg	UBERON:0001511	61.04	gold quality
tibial artery	UBERON:0007610	60.32	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	59.98	gold quality
cerebellar hemisphere	UBERON:0002245	57.03	gold quality
left adrenal gland	UBERON:0001234	54.51	gold quality
ascending aorta	UBERON:0001496	45.19	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Show downregulation of miR-195 and miR-497 from the microRNA cluster site at chromosome 17p13.1 in primary peritoneal carcinoma relative to ovarian serous carcinoma. (PMID:18677302)
• miR-497 could play a role in both gastric and lung cancer cell lines at least in part by modulation of apoptosis via targeting BCL2 (PMID:21258880)
• both miR-195 and miR-497 play important inhibitory roles in breast cancer malignancy and may be the potential therapeutic and diagnostic targets (PMID:21350001)
• ethanol-induced neuronal apoptosis follows both the mitochondria-mediated (miR-497- and BCL2-mediated) and non-mitochondria-mediated (miR-302b- and CCND2-mediated) pathway. (PMID:21878650)
• these results identify downregulation of miR-497 as an important mechanism of upregulation of IGF1-R in colorectal cancer cells that contributes to malignancy of colorectal cancer. (PMID:22710713)
• Small interfering RNA-mediated IGF-1R knockdown could mimic the effect of enforced miR-497 expression on the malignant phenotypes of cervical cancer cells (PMID:23453369)
• miR-497 is a candidate tumor suppressor in neuroblastoma, through the direct targeting of WEE1. (PMID:23531080)
• These results suggest the molecular pathway regulating cell cycle progression to be integrally altered by downregulation of miR-195 and miR-497 expression, leading to the aberrant cell proliferation in hepatocarcinogenesis. (PMID:23544130)
• Tumor samples from non-small cell lung cancers show an inverse relationship between microRNA-497 and hepatoma-derived growth factor (HDGF) levels; ectopic expression of miR-497 significantly inhibits tumor growth and angiogenesis in a xenograft model (PMID:23673296)
• This study revealed that bufalin inhibited angiogenesis and regulated miR-497 expression and that bufalin and miR-497 acted in synergy to inhibit colorectal cancer metastasis (PMID:24375248)
• Low miR-497 expression is associated with hepatocellular carcinoma. (PMID:24464213)
• Downregulation of miR-195/497 contributed to BC progression and metastasis. (PMID:24520312)
• miR-497 attenuated the malignancy of pancreatic cancer cells and promoted sensitivity of cells to gemcitabine by directly downregulation of IGF-1R expression. (PMID:24667580)
• A reverse correlation between miR-497 and eIF4E expression was noted in gastric cancer tissues. miR-497 was frequently downregulated and was associated with aggressive clinicopathological features. (PMID:24845562)
• miR-497 inhibited ovarian cancer cell migration and invasion by targeting pro-metastatic factor SMURF1. (PMID:24858688)
• Data indicate that over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting cyclin E (CCNE1). (PMID:24909281)
• Cell hypoxia can induce the expression of miR-497 at the transcriptional level by binding with the hypoxia response element in the promoter. (PMID:25080009)
• circulating miR-497 might be a promising biomarker for AMI identification and there was high association between human miR-497 and acute myocardial infarction. (PMID:25110754)
• miR-497 expression was significantly downregulated in pancreatic cancer tissues compared with tumor-adjacent samples. Low expression of miR-497 was an independent adverse prognostic factor of pancreatic cancer. (PMID:25149530)
• Results found that miR-497 expression was downregulated in human ovarian cancer tissues and its low expression was ssociated with increased angiogenesis. Also, mir-497 was found to exert its function of anti-angiogenesis by suppressing VEGFA expression. (PMID:25176450)
• Upregulation of miR-503 was the best single discriminator of malignancy. The combination of miR-34a and miR-497 underexpression discriminated carcinomas from adenomas with 100% sensitivity and 96% specificity. (PMID:25265426)
• miR-497 is high on the list of noncoding, small, regulatory RNAs that plays important roles in the pathogenesis of some diseases and takes part in some signaling pathways in some diseases. Review. (PMID:25366590)
• Our results demonstrated that miR-497 was decreased in clear cell renal cell carcinoma tissues and may provide a potential prognostic biomarker and a potential target for therapeutic intervention. (PMID:25755771)
• These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a, which synergistically retard the growth of human lung cancer cells. (PMID:25909221)
• down-regulation of miRNA-497 in colorectal cancer may contribute to the resistance of CRC cells to 5-FU treatment (PMID:25929865)
• Evidence indicates that miRNAs have the ability to regulate the expression profiles of genes in signaling pathways associated with cerebrovascular diseases such as ischemic stroke, subarachnoid hemorrhage, and vascular dementia: miR-21 is involved in ischemic stroke pathology through atherosclerosis and provides neuroprotection, miR-497 induces neuronal death and miR-210 is upregulated in hypoxic cells. [review] (PMID:25981603)
• we demonstrate that one miR-497, is a likely negative regulator of IKKbeta (PMID:26020802)
• MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. (PMID:26238185)
• Overexpression of miR-199a and miR-497 are associated with better overall survival in diffuse large B-Cell lymphoma patients. (PMID:26251897)
• Exogenous over-expression of YAP1 partially eliminated miR-497-induced cell growth. (PMID:26316081)
• Results indicate that microRNA miR-497 directly inhibited the 3’-untranslated regions (3’ UTRs) of vascular endothelial growth factor A (VEGFA) and astrocyte elevated gene-1 (AEG-1). (PMID:26336827)
• MiR-497 may act as a breast cancer suppressor through negative regulation of Bcl-2 protein expression at the posttranscriptional levels. (PMID:26339338)
• miR-497 inhibits tumor angiogenesis and growth via targeting VEGFR2, indicating miR-497 can be explored as a potential drug candidate for cancer therapy. (PMID:26345385)
• miR-497 has a prominent role in suppression of VEGF-A-mediated non-small cell lung cancer cancer cell growth and invasion. (PMID:26485685)
• Findings indicate that miR-497 is a potent tumor suppressor that inhibits cancer phenotypes by targeting ANLN and HSPA4L in NPC. (PMID:26486082)
• Rosuvastatin inhibits MMP-9 expression by upregulating miR-497 in HUVECs and apoE knockout mice, and the combination of rosuvastatin and probucol enhances this effect. (PMID:26502925)
• we have established a serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) that could distinguish CC from CIN and healthy controls with high accuracy. (PMID:26656154)
• Downregulation of microRNA-497 is associated with Colorectal cancer. (PMID:26673620)
• Data show that microRNAs miR-195 and miR-497 modulates osteogenic differentiation in primary human mesenchymal stromal/stem cells (MSC) and mouse MC3T3 cell line. (PMID:26683705)
• expression of miR-497 is significantly correlated with EMT in breast cancer cells by regulating Slug at the transcriptional as well as translational levels (PMID:26700673)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir497	ENSMUSG00000105220
rattus_norvegicus	Mir497	ENSRNOG00000036260

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.